FoxO3a Inhibits Tamoxifen-Resistant Breast Cancer Progression by Inducing Integrin α5 Expression

SIMPLE SUMMARY: Tamoxifen is a mainstay of adjuvant treatment for estrogen receptor α-positive (ERα+) breast tumors, which account for over 70% of all the diagnosed breast malignancies. Unfortunately, ~30% of patients initially responding to the therapy will eventually relapse with an endocrine-resi...

Descripción completa

Detalles Bibliográficos
Autores principales: Ricci, Elena, Fava, Mariarosa, Rizza, Pietro, Pellegrino, Michele, Bonofiglio, Daniela, Casaburi, Ivan, Lanzino, Marilena, Giordano, Cinzia, Bruno, Rosalinda, Sirianni, Rosa, Barone, Ines, Sisci, Diego, Morelli, Catia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8750403/
https://www.ncbi.nlm.nih.gov/pubmed/35008379
http://dx.doi.org/10.3390/cancers14010214

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8750403/
https://www.ncbi.nlm.nih.gov/pubmed/35008379
http://dx.doi.org/10.3390/cancers14010214

Ejemplares similares